Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Intellia Therapeutics, Inc. is not a good value stock. Intellia Therapeutics, Inc. is not a good growth stock. Intellia Therapeutics, Inc. is not very popular among insiders. Intellia Therapeutics, Inc. is a mediocre stock to choose.
Log in to see more information.
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides...
NTLA Fundamental Data by TradingView

News

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting

Globe Newswire First presentation of detailed Phase 2 results following previous positive topline announcement that study of NTLA-2002 met primary and all secondary endpoints Intellia to host investor webcast on...\n more…

Expert Outlook: Intellia Therapeutics Through The Eyes Of 7 Analysts
Expert Outlook: Intellia Therapeutics Through The Eyes Of 7 Analysts

Benzinga During the last three months, 7 analysts shared their evaluations of Intellia Therapeutics NTLA, revealing diverse outlooks from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.\n more…

We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate
We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate

Simply Wall St There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...\n more…

Cathie Wood's ARK Investment bought 186K shares of Intellia Therapeutics today
Cathie Wood's ARK Investment bought 186K shares of Intellia Therapeutics today

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Globe Newswire CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...\n more…

Intellia Therapeutics (NTLA) Receives a Buy from Truist Financial
Intellia Therapeutics (NTLA) Receives a Buy from Truist Financial

TipRanks Financial Blog Truist Financial analyst Joon Lee maintained a Buy rating on Intellia Therapeutics (NTLA - Research Report) today. The company's shares closed last...\n more…